Kaletra
Hepatitis C, Chronic, Hepatitis C, Chronic, Obesity + 3 more
Treatment
1 FDA approval
20 Active Studies for Kaletra
Treatment for
Hepatitis C, Chronic
What is Kaletra
Ritonavir
The Generic name of this drug
Treatment Summary
Ritonavir is a medication used to treat HIV by blocking the virus from reproducing. It is usually given in combination with other protease inhibitors, such as Technivie, Holkira Pak, and Viekira Pak. It is also used to treat chronic hepatitis C genotypes 1a and 1b, either with or without cirrhosis, in combination with Ribavirin. Ritonavir can increase the effectiveness of other protease inhibitors and should not be used in combination with HIV-1 protease inhibitor treatments as it can lead to drug resistance.
Kaletra
is the brand name
Kaletra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kaletra
Ritonavir
2000
50
Approved as Treatment by the FDA
Ritonavir, also called Kaletra, is approved by the FDA for 1 uses which include HIV .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with null
Effectiveness
How Kaletra Affects Patients
Ritonavir is a medication used to treat HIV-1. It works by blocking a part of HIV called protease, which is necessary for HIV to spread and cause infection. Ritonavir stops the spread of HIV by preventing the formation of infectious viral particles. It is usually taken in combination with other anti-HIV drugs and requires a low dose of ritonavir to increase its effectiveness.
How Kaletra works in the body
Ritonavir is used to fight HIV by blocking the enzyme that cuts up proteins needed by the virus to replicate. It also blocks the cytochrome P450 enzyme in the intestines and liver, which helps prevent other protease inhibitors from being transported or released from cells. This makes it harder for HIV to spread.
When to interrupt dosage
The proposed measure of Kaletra is contingent upon the diagnosed condition, including weight 40 kg or more, HIV (Human Immunodeficiency Virus) and Mild to Moderate COVID-19. The dosage shifts, based on the delivery procedure (e.g. Oral or Tablet, film coated - Oral) featured in the following table.
Condition
Dosage
Administration
COVID-19
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
Hepatitis C, Chronic
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
Hepatitis C, Chronic
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
HIV
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
Obesity
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
SARS-CoV-2 Positive Patients
, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL
Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral
Warnings
Kaletra has twenty-five contraindications, so it should not be taken while battling the conditions mentioned in the following table.
Kaletra Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulmonary Arterial Hypertension
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Kaletra.
Common Kaletra Drug Interactions
Drug Name
Risk Level
Description
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Ritonavir.
Alfuzosin
Major
The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Ritonavir.
Amodiaquine
Major
The metabolism of Amodiaquine can be decreased when combined with Ritonavir.
Anagrelide
Major
The metabolism of Anagrelide can be increased when combined with Ritonavir.
Kaletra Toxicity & Overdose Risk
There is little known about the effects of ritonavir overdose in humans, though one patient experienced tingling sensations after taking 1500 mg per day for two days. One post-marketing case has been reported of kidney failure and an allergy-like reaction. Rat tests suggest that it would take more than 2500 mg/kg to be lethal, and that other side effects could include liver damage, inflammation of the pancreas, or an allergic reaction.
Kaletra Novel Uses: Which Conditions Have a Clinical Trial Featuring Kaletra?
43 active trials are currently being conducted to assess the potential of Kaletra in alleviating Chronic hepatitis C genotype 1a, weight 40 kg or more and HIV (Human Immunodeficiency Virus) symptoms.
Condition
Clinical Trials
Trial Phases
COVID-19
0 Actively Recruiting
Obesity
0 Actively Recruiting
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Hepatitis C, Chronic
0 Actively Recruiting
Hepatitis C, Chronic
0 Actively Recruiting
SARS-CoV-2 Positive Patients
0 Actively Recruiting
Kaletra Reviews: What are patients saying about Kaletra?
5
Patient Review
4/14/2008
Kaletra for HIV
5
Patient Review
9/20/2010
Kaletra for HIV
5
Patient Review
2/21/2009
Kaletra for HIV
5
Patient Review
12/24/2009
Kaletra for HIV
5
Patient Review
6/24/2014
Kaletra for Prevention of HIV Infection after Exposure
4.7
Patient Review
4/28/2010
Kaletra for HIV
4.7
Patient Review
1/2/2016
Kaletra for HIV
4.7
Patient Review
10/28/2007
Kaletra for HIV
4.3
Patient Review
12/7/2007
Kaletra for HIV
4.3
Patient Review
5/17/2013
Kaletra for HIV
4
Patient Review
10/27/2008
Kaletra for HIV
4
Patient Review
12/14/2011
Kaletra for HIV
3.7
Patient Review
10/23/2007
Kaletra for HIV
Patient Q&A Section about kaletra
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there a generic for Kaletra?
"Kaletra is a combination of two medications, lopinavir and ritonavir, that is FDA approved for the treatment of HIV-1 infection in adult and pediatric patients. The generic formulations of Kaletra are being manufactured by Lannett and Camber Pharmaceuticals."
Answered by AI
What are the side effects of Kaletra?
"The following effects may occur: diarrhea, nausea, vomiting, stomach upset, gas, headache, and trouble sleeping. If you experience any of these effects for an extended period of time, or if they worsen, tell your doctor or pharmacist. Keep in mind that your doctor prescribed this medication because they believe that the benefits of taking it outweigh the potential risks of side effects."
Answered by AI
What is Kaletra prescribed for?
"KALETRA can decrease the amount of HIV in your blood and increase your CD4+ cell counts.
A prescription medicine, KALETRA is taken with other antiretroviral medicines to treat human immunodeficiency virus-1 (HIV-1) infection in adults and children aged 14 days or older. HIV is the virus that causes AIDS (acquired immune deficiency syndrome). KALETRA works by decreasing the amount of HIV in your blood and increasing CD4+ cell counts."
Answered by AI